SET contributes THB 40 million to locally developed Covid -19 vaccine

The Stock Exchange of Thailand (SET) has donated THB 40 million (approx. USD 1.20 million) to support two development projects by Thai medical teams and experts on Covid-19 vaccine.

1) Baiya vaccine is developed by the Faculty of Pharmaceutical Sciences, Chulalongkorn University,

2) ChulaCov19 is developed by the Faculty of Medicine, Chulalongkorn University and Chulalongkorn Memorial Hospital – the Thai Red Cross Society, in line with the government’s policy to help speed up the progress of research and development (R&D) of the Thai vaccines to success.

RelatedArticles

The Stock Exchange of Thailand (SET) unveils the SET ESG Ratings for 2024

December 17, 2024

Thai Stock Exchange unveils a 3-year strategic plan (2025-2027) aimed at enhancing opportunities for the public

December 12, 2024

US ‘Magnificent Seven’ Stock DLCs Launched During Asian Market Hours

December 10, 2024

Singapore’s Most Traded Stocks Average Double-Digit Returns in 2H24

December 9, 2024

SET President Pakorn Peetathawatchai said that even though the COVID-19
situation in Thailand has improved, it is still necessary to ensure that Thais
are immune to the virus in the long run.

Having vaccine R&D and innovations in Thailand by the Thai teams will help tackle the situations with less budget than importing them from abroad. SET aims to play a part in helping people and society by donating THB 40 million for the development of both projects which need a lot of funding.

The donation is in accordance with SET’s intention to promote Thai innovations that can lead to tangible results, and the vaccine development projects are also in line with SET’s vision “To Make the Capital Market ‘Work’ for Everyone”.

Read More